LipitenCliDec Study - the profile of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in the Czech Republic: the 2nd phase results
Abstract
In the previous issue of this journal - AtheroReview 2020; 5(1): 47-52 - the baseline data of the LipitenCliDec study (ie, the results of the first phase) were published. Study aim was to map the characteristics of patients with decompensated arterial hypertension (AH) and / or dyslipidemia (DLP), to identify possible explanatory causes of poor control of these risk factors (RF), to evaluate changes in their control 3-6 months after the initial intervention and, last but not least, the selection of patients with suspected familial hypercholesterolemia (FH).
The methodology and basic characteristics have already been mentioned in the previous article, so it will not be discussed further. The aim of this paper is to evaluate the change in control of AH/DLP and to analyze in detail the pharmacotherapy of the population and to discuss the obtained data.
The results of the presented study show that even in the short term more satisfactory controls of AH/DLP can be achieved, almost doubling the percentage of patients in which these parameters are controlled. As in the series of EUROASPIRE and LIPIcontrol, for example, we again document a better control of AH, when combination therapy (ACEi + BKK + diuretics) is correctly selected, while DLP is properly treated with modern statins (atorvastatin or rosuvastatin), but unfortunately in rela-tively small doses (10-20mg) and the use of combination therapy to affect LDL-cholesterol levels is rather sporadic, so the percentage of patients with uncontrolled DLP is much higher than with AH.
The LipitenCliDec study demonstrates the satisfactory pene-tration of current guidelines into routine clinical practice, when adequate cardioprotective therapy is correctly selected, but this is often titrated with too much caution or omitted with appropriate combination therapy.